{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T11:51:22Z","timestamp":1790077882500,"version":"4.0.1"},"reference-count":24,"publisher":"American Society for Microbiology","issue":"12","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2015,12]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    We studied the efficacy of the investigational drug VT-1161 against mucormycosis. VT-1161 had more potent\n                    <jats:italic>in vitro<\/jats:italic>\n                    activity against\n                    <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Rhizopus arrhizus<\/jats:named-content>\n                    var.\n                    <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">arrhizus<\/jats:named-content>\n                    than against\n                    <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">R. arrhizus<\/jats:named-content>\n                    var.\n                    <jats:italic>delemar<\/jats:italic>\n                    . VT-1161 treatment demonstrated dose-dependent plasma drug levels with prolonged survival time and lowered tissue fungal burden in immunosuppressed mice infected with\n                    <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">R. arrhizus<\/jats:named-content>\n                    var.\n                    <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">arrhizus<\/jats:named-content>\n                    and was as effective as high-dose liposomal amphotericin B treatment. These results support further development of VT-1161 against mucormycosis.\n                  <\/jats:p>","DOI":"10.1128\/aac.01437-15","type":"journal-article","created":{"date-parts":[[2015,9,14]],"date-time":"2015-09-14T21:51:14Z","timestamp":1442267474000},"page":"7815-7817","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":55,"title":["VT-1161 Protects Immunosuppressed Mice from Rhizopus arrhizus var. arrhizus Infection"],"prefix":"10.1128","volume":"59","author":[{"given":"Teclegiorgis","family":"Gebremariam","sequence":"first","affiliation":[{"name":"The Division of Infectious Diseases, Los Angeles Biomedical Research Institute at Harbor-University of California Los Angeles (UCLA) Medical Center and St. John's Cardiovascular Research Center, Torrance, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan P.","family":"Wiederhold","sequence":"additional","affiliation":[{"name":"University of Texas Health Sciences at San Antonio, San Antonio, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette W.","family":"Fothergill","sequence":"additional","affiliation":[{"name":"University of Texas Health Sciences at San Antonio, San Antonio, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward P.","family":"Garvey","sequence":"additional","affiliation":[{"name":"Viamet Pharmaceuticals, Inc., Durham, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William J.","family":"Hoekstra","sequence":"additional","affiliation":[{"name":"Viamet Pharmaceuticals, Inc., Durham, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Schotzinger","sequence":"additional","affiliation":[{"name":"Viamet Pharmaceuticals, Inc., Durham, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas F.","family":"Patterson","sequence":"additional","affiliation":[{"name":"University of Texas Health Sciences at San Antonio, San Antonio, Texas, USA"},{"name":"South Texas Veterans Health Care System, San Antonio, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott G.","family":"Filler","sequence":"additional","affiliation":[{"name":"The Division of Infectious Diseases, Los Angeles Biomedical Research Institute at Harbor-University of California Los Angeles (UCLA) Medical Center and St. John's Cardiovascular Research Center, Torrance, California, USA"},{"name":"David Geffen School of Medicine at UCLA, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashraf S.","family":"Ibrahim","sequence":"additional","affiliation":[{"name":"The Division of Infectious Diseases, Los Angeles Biomedical Research Institute at Harbor-University of California Los Angeles (UCLA) Medical Center and St. John's Cardiovascular Research Center, Torrance, California, USA"},{"name":"David Geffen School of Medicine at UCLA, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1136\/pgmj.2008.076463"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1086\/339202"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir867"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir866"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1204781"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis749"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428190310001653691"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4419-6640-7_15"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1086\/422729"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1086\/313803"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1086\/375822"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04902-14"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2014.05.068"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.13.2.236-301.2000"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1086\/432579"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/myc.12228"},{"key":"e_1_3_2_18_2","volume-title":"CLSI document M38-A2","author":"Clinical and Laboratory Standards Institute","year":"2008","unstructured":"Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. CLSI document M38-A2. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00313-13"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.10.3343-3344.2003"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.2.721-727.2005"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.2165\/0003088-200847120-00003"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03707-14"},{"key":"e_1_3_2_24_2","volume-title":"American Society for Microbiology","author":"Shubitz LF","year":"2014","unstructured":"Shubitz LF, Trinh HT, Galgiani JN, Lewis ML, Garvey EP, Hoekstra WJ, Moore WR, Schotzinger RJ. 2014. CT-1161, a novel fungal CYP51 inhibitor, improved survival in murine models of coccidioidomycosis. In Abstr 54th Intersci Conf Antimicrob Agents Chemother. American Society for Microbiology, Washington, DC."},{"key":"e_1_3_2_25_2","volume-title":"Abstr 54th Intersci Conf Antimicrob Agents Chemother. American Society for Microbiology","author":"Fothergill AW","year":"2014","unstructured":"Fothergill AW, McCarthy DI, Sutton DA, Garvey EP, Hoekstra WJ, Moore WR, Schotzinger RJ, Wiederhold NP. 2014. The fungal Cyp51 inhibitor VT-1161 demonstrates in vitro synergy with tacrolimus against Aspergillus spp. and members of the order Mucorales. Abstr 54th Intersci Conf Antimicrob Agents Chemother. American Society for Microbiology. Washington, DC."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01437-15","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01437-15","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T18:03:09Z","timestamp":1645466589000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01437-15"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":24,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["10.1128\/AAC.01437-15"],"URL":"https:\/\/doi.org\/10.1128\/aac.01437-15","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"2015-06-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-09-11","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-11-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}